28 Sep, 2025 New Data from HELIOS-B Phase 3 Study Presented at the Heart Failure Society Annual Scientific Meeting
Late-breaking abstract from the HELIOS-B Phase 3 study showed vutrisiran significantly lowered rates of gastrointestinal events, a common disease manifestation of ATTR-CM, by up to 49% in patients.
Additional HELIOS-B analyses validate the efficacy and safety of vutrisiran as a monotherapy in ATTR-CM and support the consistent benefit of vutrisiran treatment in ATTR-CM patients regardless of baseline health status and quality of life.